{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T21:55:16Z","timestamp":1794002116435,"version":"4.8.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca PLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.annonc.2026.05.693","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T15:50:59Z","timestamp":1779292259000},"page":"1081-1092","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Datopotamab deruxtecan (Dato-DXd) in combination with durvalumab as first-line treatment for unresectable locally advanced or metastatic triple-negative breast cancer: results from arms 7 and 8 of the phase Ib\/II BEGONIA study"],"prefix":"10.1016","volume":"37","author":[{"given":"P.","family":"Schmid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.-C.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6615-7076","authenticated-orcid":false,"given":"F.","family":"Lynce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Asselah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1580-7224","authenticated-orcid":false,"given":"K.H.","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.X.","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.H.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0177-0045","authenticated-orcid":false,"given":"S.-C.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4003-5278","authenticated-orcid":false,"given":"P.J.","family":"Wysocki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7071-6483","authenticated-orcid":false,"given":"R.D.","family":"Baird","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Nowecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2955-5523","authenticated-orcid":false,"given":"J.","family":"O\u2019Shaughnessy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7946-5609","authenticated-orcid":false,"given":"S.","family":"Lord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.-F.","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.-M.","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Prady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Rao-Melacini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Warzyszy\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Vukovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.-A.","family":"Im","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.annonc.2026.05.693_bib1","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1158\/2159-8290.CD-18-1177","article-title":"Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment","volume":"9","author":"Garrido-Castro","year":"2019","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.annonc.2026.05.693_bib2","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41523-022-00468-0","article-title":"Triple negative breast cancer: pitfalls and progress","volume":"8","author":"Zagami","year":"2022","journal-title":"NPJ Breast Cancer"},{"issue":"3","key":"10.1016\/j.annonc.2026.05.693_bib3","doi-asserted-by":"crossref","first-page":"164","DOI":"10.5306\/wjco.v12.i3.164","article-title":"Overview of recent advances in metastatic triple negative breast cancer","volume":"12","author":"O\u2019Reilly","year":"2021","journal-title":"World J Clin Oncol"},{"key":"10.1016\/j.annonc.2026.05.693_bib4","doi-asserted-by":"crossref","DOI":"10.1155\/2024\/9083055","article-title":"Targeted treatment of metastatic triple-negative breast cancer: a systematic review","volume":"2024","author":"Hammersh\u00f8i Madsen","year":"2024","journal-title":"Breast J"},{"issue":"9","key":"10.1016\/j.annonc.2026.05.693_bib5","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1634\/theoncologist.2016-0067","article-title":"Biology and management of patients with triple-negative breast cancer","volume":"21","author":"Sharma","year":"2016","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.annonc.2026.05.693_bib6","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1186\/s12885-021-08320-7","article-title":"Genomic features of rapid versus late relapse in triple negative breast cancer","volume":"21","author":"Zhang","year":"2021","journal-title":"BMC Cancer"},{"issue":"15 Pt 1","key":"10.1016\/j.annonc.2026.05.693_bib7","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","article-title":"Triple-negative breast cancer: clinical features and patterns of recurrence","volume":"13","author":"Dent","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"suppl 2","key":"10.1016\/j.annonc.2026.05.693_bib8","article-title":"How I treat metastatic triple-negative breast cancer","volume":"4","author":"Caparica","year":"2019","journal-title":"ESMO Open"},{"issue":"12","key":"10.1016\/j.annonc.2026.05.693_bib9","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2026.05.693_bib10","article-title":"Systemic treatment of patients with metastatic breast cancer: ASCO resource-stratified guideline","volume":"10","author":"Al Sukhun","year":"2024","journal-title":"JCO Glob Oncol"},{"issue":"10265","key":"10.1016\/j.annonc.2026.05.693_bib11","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial","volume":"396","author":"Cortes","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.annonc.2026.05.693_bib12","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S1470-2045(19)30689-8","article-title":"Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"21","author":"Schmid","year":"2020","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.annonc.2026.05.693_bib13","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.annonc.2021.05.355","article-title":"First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis","volume":"32","author":"Emens","year":"2021","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.annonc.2026.05.693_bib14","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.annonc.2021.05.801","article-title":"Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced\/metastatic triple-negative breast cancer","volume":"32","author":"Miles","year":"2021","journal-title":"Ann Oncol"},{"issue":"22","key":"10.1016\/j.annonc.2026.05.693_bib15","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.annonc.2026.05.693_bib16","doi-asserted-by":"crossref","first-page":"15584","DOI":"10.18632\/oncotarget.14698","article-title":"The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer","volume":"8","author":"Mori","year":"2017","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.annonc.2026.05.693_bib17","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s11523-024-01125-1","article-title":"Second-line treatment options for patients with metastatic triple-negative breast cancer: a review of the clinical evidence","volume":"20","author":"Garc\u00eda-Saenz","year":"2025","journal-title":"Target Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2026.05.693_bib18","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyaf034","article-title":"Unmet need for previously untreated metastatic triple-negative breast cancer: a real-world study of patients diagnosed from 2011 to 2022 in the United States","volume":"30","author":"Punie","year":"2025","journal-title":"Oncologist"},{"key":"10.1016\/j.annonc.2026.05.693_bib19","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Breast Cancer V.2.2026. \u00a9 National Comprehensive Cancer Network, Inc. 2026. All rights reserved. Accessed [Mar 31, 2026]. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way."},{"issue":"suppl 15","key":"10.1016\/j.annonc.2026.05.693_bib20","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1200\/JCO.2021.39.15_suppl.1023","article-title":"BEGONIA: phase 1b\/2 study of durvalumab (D) combinations in locally advanced\/metastatic triple-negative breast cancer (TNBC)\u2014initial results from arm 1, d+paclitaxel (P), and arm 6, d+trastuzumab deruxtecan (T-DXd)","volume":"39","author":"Schmid","year":"2021","journal-title":"J Clin Oncol"},{"issue":"suppl 2","key":"10.1016\/j.annonc.2026.05.693_bib21","article-title":"Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced\/metastatic triple-negative breast cancer (a\/mTNBC): updated results from BEGONIA, a phase Ib\/II study","volume":"34","author":"Schmid","year":"2023","journal-title":"Ann Oncol"},{"issue":"27","key":"10.1016\/j.annonc.2026.05.693_bib24","doi-asserted-by":"crossref","first-page":"18985","DOI":"10.18632\/oncotarget.24867","article-title":"A pilot study of durvalumab and tremelimumab and immunogenomic dynamics in metastatic breast cancer","volume":"9","author":"Santa-Maria","year":"2018","journal-title":"Oncotarget"},{"issue":"12","key":"10.1016\/j.annonc.2026.05.693_bib25","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1158\/1535-7163.MCT-21-0206","article-title":"Datopotamab deruxtecan, a novel TROP2-directed antibody-drug conjugate, demonstrates potent antitumor activity by efficient drug delivery to tumor cells","volume":"20","author":"Okajima","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.annonc.2026.05.693_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2021.03.213","article-title":"LBA4 Datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody-drug conjugate (ADC), for triple-negative breast cancer (TNBC): preliminary results from an ongoing phase I trial","volume":"32","author":"Bardia","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2026.05.693_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2026.03.008","article-title":"Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial","author":"Dent","year":"2026","journal-title":"Ann Oncol"},{"issue":"suppl 7","key":"10.1016\/j.annonc.2026.05.693_bib28","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.1158\/1538-7445.AM2023-2932","article-title":"Datopotamab deruxtecan (Dato-DXd) enhances antitumor response to PD-1\/PD-L1 inhibitors in TROP2-expressing tumors in mice","volume":"83","author":"Okajima","year":"2023","journal-title":"Cancer Res"},{"issue":"315","key":"10.1016\/j.annonc.2026.05.693_bib29","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac4925","article-title":"Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4\/PD-1 blockade","volume":"7","author":"M\u00fcller","year":"2015","journal-title":"Sci Transl Med"},{"issue":"7","key":"10.1016\/j.annonc.2026.05.693_bib30","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1158\/1535-7163.MCT-17-0749","article-title":"A HER2-targeting antibody-drug conjugate, trastuzumab deruxtecan (DS-8201a), enhances antitumor immunity in a mouse model","volume":"17","author":"Iwata","year":"2018","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"10.1016\/j.annonc.2026.05.693_bib31","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1038\/s41467-025-58266-8","article-title":"Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd)","volume":"16","author":"Tsao","year":"2025","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.annonc.2026.05.693_bib32","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.annonc.2025.10.013","article-title":"Antibody-drug conjugates in combination therapy: defining the next chapter","volume":"37","author":"Siu","year":"2026","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.annonc.2026.05.693_bib33","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.annonc.2026.05.693_bib34","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.annonc.2024.03.001","article-title":"ESMO clinical practice guideline interim update on first-line therapy in advanced urothelial carcinoma","volume":"35","author":"Powles","year":"2024","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.annonc.2026.05.693_bib35","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005119","article-title":"Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer","volume":"10","author":"Waks","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"4","key":"10.1016\/j.annonc.2026.05.693_bib36","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa2508959","article-title":"Sacituzumab govitecan plus pembrolizumab for advanced triple-negative breast cancer","volume":"394","author":"Tolaney","year":"2026","journal-title":"NEJM"},{"issue":"11","key":"10.1016\/j.annonc.2026.05.693_bib37","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.5858\/arpa.2018-0902-SA","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Focused Update","volume":"142","author":"Wolff","year":"2018","journal-title":"Arch Pathol Lab Med"},{"issue":"7","key":"10.1016\/j.annonc.2026.05.693_bib38","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.5858\/134.7.e48","article-title":"American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version)","volume":"134","author":"Hammond","year":"2010","journal-title":"Arch Pathol Lab Med"},{"issue":"9","key":"10.1016\/j.annonc.2026.05.693_bib39","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1038\/s41379-020-0544-x","article-title":"Prospective multi-institutional evaluation of pathologist assessment of PD-L1 assays for patient selection in triple negative breast cancer","volume":"33","author":"Reisenbichler","year":"2020","journal-title":"Mod Pathol"},{"issue":"4","key":"10.1016\/j.annonc.2026.05.693_bib40","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1136\/jcp-2022-208637","article-title":"Comparison of assessment of programmed death-ligand 1 (PD-L1) status in triple-negative breast cancer biopsies and surgical specimens","volume":"77","author":"Noske","year":"2024","journal-title":"J Clin Pathol"},{"issue":"19","key":"10.1016\/j.annonc.2026.05.693_bib41","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1056\/NEJMoa2511734","article-title":"Sacituzumab govitecan in untreated, advanced triple-negative breast cancer","volume":"393","author":"Cortes","year":"2025","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.annonc.2026.05.693_bib44","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-011140","article-title":"Differential safety profiles of durvalumab monotherapy and durvalumab in combination with tremelimumab in adult patients with advanced cancers","volume":"13","author":"Morgan","year":"2025","journal-title":"J Immunother Cancer"},{"issue":"3","key":"10.1016\/j.annonc.2026.05.693_bib45","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1200\/JCO.24.00920","article-title":"Datopotamab deruxtecan versus chemotherapy in previously treated inoperable\/metastatic hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer: primary results from TROPION-Breast01","volume":"43","author":"Bardia","year":"2025","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2026.05.693_bib46","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.annonc.2025.01.009","article-title":"VP1-2025: Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+\/HER2\u2013) breast cancer (BC): final overall survival (OS) from the phase III TROPION-Breast01 trial","volume":"36","author":"Pistilli","year":"2025","journal-title":"Ann Oncol"},{"issue":"19","key":"10.1016\/j.annonc.2026.05.693_bib47","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1200\/JCO.23.01909","article-title":"Datopotamab deruxtecan in advanced or metastatic HR+\/HER2\u2212 and triple-negative breast cancer: results from the phase I TROPION-PanTumor01 study","volume":"42","author":"Bardia","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2026.05.693_bib48","doi-asserted-by":"crossref","DOI":"10.1177\/17588359251327992","article-title":"TROPION-Breast05: a randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer","volume":"17","author":"Schmid","year":"2025","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.annonc.2026.05.693_bib50","doi-asserted-by":"crossref","DOI":"10.1177\/17588359241248336","article-title":"TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan \u00b1 durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy","volume":"16","author":"Bardia","year":"2024","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.annonc.2026.05.693_bib51","doi-asserted-by":"crossref","DOI":"10.1177\/17588359251316176","volume":"17","author":"McArthur","year":"2025","journal-title":"Ther Adv Med Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375342600877X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375342600877X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T20:42:18Z","timestamp":1785876138000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092375342600877X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":46,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S092375342600877X"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2026.05.693","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Datopotamab deruxtecan (Dato-DXd) in combination with durvalumab as first-line treatment for unresectable locally advanced or metastatic triple-negative breast cancer: results from arms 7 and 8 of the phase Ib\/II BEGONIA study","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2026.05.693","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}